EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From “MAFLD” to “MASLD”: Was This Revolution Worth It? A Head-to-Head Comparison of MAFLD and MASLD Criteria in Estimating Liver Disease Progression and Cardiovascular Risk in Real Life

Marcello Dallio, Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Claudio Basile, Annachiara Coppola, Alessia Silvestrin, Giusy Senese, Marco Niosi, Alessandro Federico

Livers · 12.11.2025 · 5 (4) · 58

DOI: 10.3390/livers5040058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Livers, online erschienen am 12.11.2025. Verfasst von Marcello Dallio und 10 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: In the present study, the Metabolic dysfunction-associated fatty liver disease (MAFLD) and Metabolic dysfunction-associated steatotic liver disease (MASLD) diagnostic criteria were applied to evaluate the relative performance in predicting short-term advanced fibrosis (AF) progression (AFpr) and hepatocellular carcinoma (HCC), as well as an ancillary outcome, i.e., the occurrence of acute cardiovascular events (ACEs) in steatotic liver disease (SLD) patients.

Methods

We retrospectively analyzed the data stored in the University Hospital (UH)’s Official Health Documents Digitization Archive of 931 SLD patients, with a follow-up of 3 years. Based on the Body Mass Index (BMI), patients were subdivided into lean “L” (BMI < 25 kg/m2) (n = 134) and not-lean “NL” (n = 797), and, subsequently, into NL-MASLD (n = 206), NL-MASLD/MAFLD (n = 481), NL-MAFLD (n = 110), L-MASLD (n = 39), L-MASLD/MAFLD (n = 68), and L-MAFLD (n = 27). All study outcomes (AFpr, HCC, and ACE) were primarily evaluated in NL-SLD and by conducting a sub-analysis of L-SLD individuals.

Results

MASLD and MAFLD criteria similarly estimated [p = 0.076] the overall 3-year risk of AF progression in NL-SLD. In the L-SLD sub-analysis, MAFLD criteria better estimated the overall 3-year risk of AF progression [p = 0.006]. Multivariate competing risk analysis (adjusted for sex, age, diabetes, steatosis, and fibrosis severity) revealed diabetes [adjusted Hazard Ratio (aHR) = 2.113, p = 0.001], high-sensitivity C-reactive protein (aHR = 1.441; p = 0.02), and Homeostatic Model Assessment for Insulin Resistance (aHR = 1.228; p = 0.03) as being associated with AF progression in L-MAFLD. Compared to MAFLD, MASLD diagnostic criteria similarly estimated the 3-year risk of HCC occurrence both in NL [HR = 1.104, C.I. 95%: 0.824–1.593, p = 0.741] and L [HR = 1.260, C.I. 95%: 0.768–2.104, p = 0.701] patients. Finally, no significant differences were reported between the MAFLD or MASLD criteria for ACE risk occurrence in all study groups.

Conclusions

The MAFLD criteria better estimate the AF progression risk, limited to L-SLD patients.

Zitieren

APA

Dallio, M., Romeo, M., Nardo, F. D., Napolitano, C., Vaia, P., Basile, C., Coppola, A., Silvestrin, A., Senese, G., Niosi, M., & Federico, A. (2025). From “MAFLD” to “MASLD”: Was This Revolution Worth It? A Head-to-Head Comparison of MAFLD and MASLD Criteria in Estimating Liver Disease Progression and Cardiovascular Risk in Real Life. Livers, 5(4), 58. https://doi.org/10.3390/livers5040058

Vancouver

Dallio M, Romeo M, Nardo FD, Napolitano C, Vaia P, Basile C, et al. From “MAFLD” to “MASLD”: Was This Revolution Worth It? A Head-to-Head Comparison of MAFLD and MASLD Criteria in Estimating Liver Disease Progression and Cardiovascular Risk in Real Life. Livers. 2025;5(4):58. doi:10.3390/livers5040058

BibTeX
@article{Dallio2025,
  author = {Dallio, Marcello and Romeo, Mario and Nardo, Fiammetta Di and Napolitano, Carmine and Vaia, Paolo and Basile, Claudio and Coppola, Annachiara and Silvestrin, Alessia and Senese, Giusy and Niosi, Marco and Federico, Alessandro},
  title = {From “MAFLD” to “MASLD”: Was This Revolution Worth It? A Head-to-Head Comparison of MAFLD and MASLD Criteria in Estimating Liver Disease Progression and Cardiovascular Risk in Real Life},
  journal = {Livers},
  year = {2025},
  volume = {5},
  number = {4},
  pages = {58},
  doi = {10.3390/livers5040058}
}
Kostenlos starten →